Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 161

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 161
---
 treatments . Sales also benefited from supplies to Sanofi’s partner in Europe, where the medicine obtained regulatory approval. Total hemophilia A franchise sales (ALTUVIIIO + Eloctate) amounted to € 1,050 million (+ 67.8% CER), representing an increase in Sanofi’s market share of factor- based treatments as well as of the overall hemophilia A market. Nexviazyme/Nexviadyme (Pompe disease) sales were € 667 million (including € 361 million in the United States), up 61.2% year-on- year , driven by switches from Myozyme/Lumizyme in the eligible late-onset Pompe disease popula tion and by an increase in new patients. Total sales for the Pompe franchise (Nexviazyme/Nexviadyme + Myozyme/Lumizyme) were € 1,338 million. Nexviazyme/ Nexviadyme now account for 50% of total Pompe franchise sales. Sarclisa (multiple myeloma) reported sales of € 471 million, up 29.7% CER, driven by strong growth in all three regions. Sales reached € 200 million in the United States ( +21.2% CER), € 134 million in Europe ( +20.7% CER), and € 137 million in the Rest of the World region ( +52.4% CER). Sales of Rezurock (chronic graft-versus-host disease) were € 470 million in 2024 , an increase of 51.6% CER, driven by continued strong uptake in the US (€ 425 million, + 40.6% CER) , where the product is becoming the standard of care in the indicated setting , and by rapid uptake in launch countries (especially China and the United Kingdom). Globally, more than 9,400 patients have been prescribed Rezurock (including 830 patients in early access or managed access programs) since launch, key drivers being the product's real-world efficacy, tolerability and oral route of administration. Cablivi (acquired thrombotic thrombocytopenic purpura) reported 2024 sales of € 249 million ( +9.7% CER), including € 136 million ( +21.4% CER) in the United States driven by patient growth. Xenpozyme (acid sphingomyelinase deficiency)